Roth/MKM maintained a positive stance on Canopy Growth (NASDAQ:CGC) shares, despite reducing the price target to C$10 from the previous C$15. The firm continues to endorse a Buy rating for the ...

Canopy’s stock reversed on earnings after seeing a rally sparked by the possibility of marijuana reform in the U.S.

Canopy Growth (TSE:WEED – Get Free Report) had its target price lowered by equities research analysts at ATB Capital from C$4.00 to C$3.20 in a research note issued on Monday,BayStreet.CA reports. The ...

Be cautious ahead of Canopy Growth Corporation's FQ3 results, as weak financials and low margins may hinder stock performance ...

Alliance Global Partners analyst Aaron Grey lowered the firm’s price target on Canopy Growth (CGC) to C$4 from C$7 and keeps a Neutral rating ...

Canopy Growth (TSE:WEED – Get Free Report) had its target price decreased by analysts at Canaccord Genuity Group from C$2.50 to C$1.50 in a research report issued to clients and investors on ...

Canopy Growth (CGC) stock drops 15% in premarket after the company posted wider Q3 loss due to revenue and gross margin declines. Read more here.

Reports Q3 revenue C$74.8M vs. C$78.5M last year. “Canopy Growth’s (CGC) third quarter highlights that our business has the right ingredients ...

Canopy Growth Corporation ("Canopy Growth" or the ... political delays and market volatility have affected cannabis stock. "We keep expecting federal reform, we keep getting promised federal ...

Canopy Growth Q3 sales hit C$74.76 million, surpassing estimates. Medical cannabis revenue rose 16%, while adjusted EBITDA loss improved 61% year-over-year.